Ajanta Pharma gets approval for Clonidine Hydrochloride Extended Release Tablets

Image
Capital Market
Last Updated : Nov 21 2017 | 4:50 PM IST

From USFDA

Ajanta Pharma announced that the Company has received the final approval for Clonidine Hydrochloride Extended Release Tablets from US FDA and the same has been launched in US Market through its wholly owned subsidiary, Ajanta Pharma USA Inc.

It is a bioequivalent generic version of Kapvay1 Tablets and company has launched the product in 0.1mg dosage

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 21 2017 | 4:31 PM IST

Next Story